Cancer chemotherapy and infusional scheduling

Area of Science:

• Oncology
• Pharmacology
• Cancer Therapeutics

Background:

• The practice of infusional cancer chemotherapy has evolved significantly over the past decade.
• Increased understanding of tumor cell kinetics and drug pharmacology highlights the importance of the concentration x time formulation.
• Technological advancements in vascular access and infusion pumps have improved drug delivery capabilities.

Purpose of the Study:

• To review the evolution and impact of infusional chemotherapy over the past decade.
• To highlight the benefits of infusional schedules regarding tumor cell killing and host tolerance.
• To assess the therapeutic index of infusional administration across various antineoplastic agents.

Main Methods:

• Review of infusional chemotherapy practices and their outcomes over the last 10 years.
• Analysis of data regarding tumor cell kinetics and drug pharmacology in relation to infusion schedules.
• Examination of technological advancements enabling practical infusional drug delivery.

Main Results:

• Infusional schedules have been applied to nearly all classes of antineoplastic agents.
• Demonstrated improved therapeutic index through reduced or altered toxicity (e.g., doxorubicin, fluorouracil, ifosfamide, platinum analogs).
• Showcased increased tumor cell killing with specific agents (e.g., fluorouracil, etoposide, cladribine).

Conclusions:

• Infusional chemotherapy administration alters toxicity profiles and maintains therapeutic benefit.
• Evidence suggests that infusional schedules do not diminish therapeutic benefit compared to bolus administration.
• The concentration x time formulation is crucial for optimizing infusional chemotherapy efficacy and safety.